Review of the State of the Art and Recommendations of the Papanicolaou Society of Cytopathology for Urinary Cytology Procedures and Reporting: The Papanicolaou Society of Cytopathology Practice Guidelines Task Force

Diagnostic Cytopathology

Volumn 30, Issue 1, 2004, Pages 24-30

  Layfield, Lester J ^a   Elsheikh, Tarik M ^b   Fili, Armando ^c   Nayar, Ritu ^d   Shidham, Vinod ^e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b BALL MEMORIAL HOSPITAL   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

BLADDER; BLADDER TUMOR; CANCER CLASSIFICATION; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER GRADING; CHROMOSOME ANALYSIS; CYSTECTOMY; CYTOLOGY; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; ILEAL CONDUIT; KIDNEY PELVIS; MEDICAL SOCIETY; PAPANICOLAOU TEST; PAPILLARY CARCINOMA; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESSING; PROGNOSIS; QUALITY CONTROL; REVIEW; SAMPLING; TECHNIQUE; TRANSITIONAL CELL CARCINOMA; URETER; URETHRA; URINALYSIS; URINE; URINE CYTOLOGY; UROGENITAL TRACT CANCER; WORLD HEALTH ORGANIZATION;

CYTOLOGY; HISTOCYTOLOGICAL PREPARATION TECHNIQUES; HUMANS; PATHOLOGY, CLINICAL; URINALYSIS; UROLOGIC DISEASES; VAGINAL SMEARS;

EID: 0347991899     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.10401     Document Type: Review

References (63)

1. Thompson S. Assyrian prescription for diseases of the urine. Babyloniara 1934;14:108-109.
2. Wershab LP. Urology. From antiquity to the 20th century. St. Louis: Warren H. Green; 1970.
3. Bardales RH. Practical urologic cytopathology. New York: Oxford University Press; 2002. p 5-8.
4. Long SR, Cohen MB. Classics in cytology. V. William Sanders and early urinary tract cytology. Diagn Cytopathol 1992;8:135-136.
5. Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945;101:519-521.
6. Koss LG, Melamed MR, Kelly RE. Further cytologic and histologic studies of bladder lesions in workers exposed to para-aminodiphenyl: progress report. J Natl Cancer Inst 1969:43:233-243.
7. Melamed MR, Koss LG, Ricci A, Whitmore WF Jr. Cytohistological observations on developing carcinomas of urinary bladder in men. Cancer 1960;13:67-74.
8. Koss LG. Tumors of the urinary bladder. Atlas of tumor pathology, second series. Fascisle II. Washington, DC: Armed Forces Institute of Pathology: 1975.
9. Oyasu R. World Health Organization and International Society of Urological Pathology Classification and two-number grading system of bladder tumors. Cancer 2000:88:1509-1512.
10. Epstein JI, Amin MB, Reuter UR, Mostofi EK, and The Bladder Consensus Conference Committee. The World Health Organization/ International Society of Urological Pathology Consensus classification of urothelial (transitional cell) neoplasms of the urinary bladdder. Am J Surg Pathol 1998:22:1435-1488.
11. Renshaw AA. Subclassifying atypical urinary cytology specimens. Cancer 2000:90:222-229.
12. Lopez-Beltran A. Bladder treatment. Immunotherapy and chemotherapy. Urol Clin North Am 1999:26:535-554.
13. Loveless KJ. The effects of radiation upon the cytology of benign and malignant bladder epithelia. Acta Cytol 1973:17:355-360.
14. Malmgren RA, Soloway MS, Chu EW, DelVecchio PR, Ketcham AS. Cytology of ileal conduit urine. Acta Cytol 1971:15:506-509.
15. Sarosdy MF, DeVere White RW, Sheinfeld SJ, et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol 1995:154:379-384.
16. Kinders R, Jones T, Root R, et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998:4:2511-2520.
17. Waldman FM, Carroll PR, Kerschmann R, et al. Centrometric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res 1991:51:3807-3813.
18. Smeets AWGB, Schapers R, Hompan AHN, et al. Concordance between karyotyping and in situ hybridization procedures in the detection of monosomy 9 bladder cancer. Cancer Genet Cytogenet 1993:71:97-99.
19. Sauter G, Moch H, Wagner U, et al. Y chromosome loss detected by FISH in bladder cancer. Cancer Genet Cytogenet 1995:82:163-169.
20. Matsuyama H, Bergerheim USR. Nilsson I, et al. Nonrandom numerical aberrations of chromosomes 7. 9. and 10 in DNA-diploid bladder cancer. Cancer Genet Cytogenet 1994;77:118-124.
21. Hopman AHN, Moesker O, Smeets AWGB, et al. Numerical chromosome 1, 7, 9, and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res 1991;51:644-651.
22. Cajulis RS, Haines GK, Frias-Hidvegi D, et al. Cytology, flow cytometry, image analysis and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn Cytopathol 1997;13:214-224.
23. Meloni AM, Peier AM, Haddad FS, et al. A new approach in the diagnosis and follow-up of bladder cancer: FISH analysis of urine, bladder washings, and tumors. Cancer Genet Cytogenet 1993:71:105-118.
24. Ellwein LB. Bladder cancer screening: lesions from a biologically based model of bladder cancer progression and therapeutic intervention. J Occup Med 1990:32:806-811.
25. Farrow GM. Urine cytology in the detection of bladder cancer: A critical approach. J Occup Med 1990:32:817-821.
26. Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer. Urol Clin N Am 1992;19:435-453.
27. Dodd LG, Johnston WW, Robertson CN, Layfield LJ. Endoscopic brush cytology of the upper urinary tract: Evaluation of its efficiency and potential limitations in diagnosis. Acta Ctyol 1997:41:377-384.
28. Farrow GM. Urine cytology of transitional cell carcinoma. Diagnostic efficacy. In: Wied GL, Keebler CM, Koss LG, Reagan JW, editors. Compendium on diagnostic cytology. 6th ed. Chicago: Tutorials of Cytology; 1998. p 410-411.
29. Koss LG, Deitch D, Ramanathan R, Sherman AB. Diagnostic value of cytology of voided urine. Acta Cytol 1985:29:810-816.
30. Hastie KJ, Ahmad R, Moisey CU. Fractionated urinary cytology in the follow-up of bladder cancer. Br J Urol 1990;66:40-41.
31. Slaton JW, Dinney CP, Veltri RW, et al. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol 1997;158:806-811.
32. Pfister RR. Endoscopy and the detection of genitourinary carcinoma. Cancer 1976;37:471-474.
33. Grossman HB. Diagnosis and treatment of bladder carcinoma. Compr Ther 1986;12:42-47.
34. van der Poel HG, Witjes JA, van Stratam P, Boon ME, Debruyne FM, Schalker JA. Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer. Urology 1996;48:357-364.
35. Skinner EC, Skinner DG. Management of bladder cancer. In: O-Donnell PD, editor. Geriatric urology. Boston: Little Brown: 1994. p 157-165.
36. Shokeir AA, Shamaa M, el Mekresh MM, el-Baz M, Ghoneim MA. Late malignancy in bowel segments exposed to urine without fecal stream. Urology 1995;46:657-661.
37. Kern WH. Urinary tract. In: Bibbo M, ed. Comprehensive cytopathology, 2nd ed. Philadelphia: W.B. Saunders: 1997. p 446-449.
38. Kern WH, Bales CE. Quantitative studies of urine cytology. Am J Clin Pathol 1969:51:225-228.
39. Pearson JC, Kromhout L, King EB. Evaluation of collection and preservation techniques for urinary cytology. Acta Cytol 1981;25:327-333.
40. Ash JE. Epithelial tumors of the bladder. J Urol 1940;44:135-145.
41. Mostofi FK. Standardization of nomenclature and criteria for diagnosis of epithelial tumors of urinary bladder. Acta Unio Int Contra Cancer 1960;16:310-314.
42. Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumors based on the cellular pattern. Acta Chir Scand 1965;130:371-378.
43. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumors. In: International classification of tumors. No. 10 Geneva: World Health Organization: 1973. p 15-17.
44. Murphy WM, Beckwith JB, Farrow GM. Tumors of the kidneys, bladder and related urinary structures. In: Rosai J, editor. Atlas of tumor pathology, 3rd series fascicle. Washington, DC: Armed Forces Institute of Pathology: 1994. p 198-248.
45. Murphy WM. Bladder cancer redefined [Editorial]. Cancer 1999;86: 1890-1892.
46. Jordan AM, Weingarten J, Murphy WM. Transitional cell neoplasms of the urinary bladder: can biological potential be predicted from histologic grading? Cancer 1987;60:2766-2779.
47. Kaubisch S, Lum BL, Reese J, Freiha F, Torti FM. Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol 1991;146:28-31.
48. Bastacky S, Ibrahim S, Wilezynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer Cytopathol 1999;87:118-128.
49. Renshaw AA, Nappi D, Weinberg DS. The cytology of grade I papillary transitional cell carcinoma: a comparison of cytologic, architectural and morphometric criteria in cytoscopically obtained urine. Acta Cytol 1996:40:676-682.
50. Renshaw AA. Compassionate conservatism in urinary cytology [Editorial]. Diagn Cytopathol 2000:22:137-138.
51. Curry JL, Wojcik EM. The effects of the current World Health Organization/International Society of Urologic Pathologists bladder neoplasm classification system on urine cytology results. Cancer (Cytopathology) 2002;96:140-145.
52. Huben RP, Gaeta J. Pathology and its importance in evaluating outcome in patients with superficial bladder cancer. Semin Urol Oncol 1996;14:23-29.
53. Miyanaga N, Akaza H, Ishikinva S, et al. Clincial evaluation of nuclear matrix protein 22 in (NMP22) in urine as a novel marker of urothelial cancer. Eur Urol 1997;31:163-168.
54. McCabe R, Lamm D, Haspel M, et al. A diagnostic-prognostic test for bladder cancer using monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin(nogen) degradation products. Cancer 1984;44:5886-5893.
55. Burchardt M, Burdardt T, Shabsigh A, de la Taille A, Benson M, Sawczuk I. Current concepts in biomarker technology for bladder cancers. Clin Chem 2000;46:595-605.
56. Lowe S, Bodis S, McClatchye A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810.
57. Sarkis A, Dalbagni G, Cordon-Cardo C, et al. Nuclear over-expression of p53 protein in transitional cell bladder carcinoma: a marker of disease progression. J Natl Cancer Inst 1993;85:53-59.
58. Malkowicz S. The application of human compliment factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin N Am 2000;27:63-73.
59. Murphy W, Rivera-Rimerez I, Meina C, et al. The bladder tumor antigen (BTA) test compared to urine cytology in the detection of bladder neoplasms. J Urol 1997;158:2102-2106.
60. Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164:1768-1775.
61. Nasuti JF, Gomella LG, Ismial M, Bibbo M. Utility of the BTA stat test kit for bladder cancer screening. Diagn Cytopathol 1999;21:27-29.
62. Sokolova IA, Halling KC, Jenkins RB, et al. The development of a multi-targeted multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinomas in urine. J Mol Diagn 2000;2: 116-123.
63. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 2002:287:2114-2119.